SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and PTC Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Therapeutics

In the competitive landscape of biotechnology, managing operational expenses is crucial for sustainable growth. Over the past decade, PTC Therapeutics, Inc. and TG Therapeutics, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.

PTC Therapeutics, Inc.

From 2014 to 2023, PTC Therapeutics saw a consistent rise in SG&A expenses, peaking at approximately $332 million in 2023. This represents a staggering 640% increase from their 2014 expenses. Such growth reflects their aggressive expansion and investment in administrative capabilities.

TG Therapeutics, Inc.

Conversely, TG Therapeutics maintained a more conservative approach, with their SG&A expenses increasing by around 400% over the same period, reaching about $123 million in 2023. This strategy may indicate a focus on lean operations while still supporting their growth ambitions.

These insights highlight the diverse strategies employed by biotech firms in managing operational costs, crucial for investors and stakeholders to consider.